drugset
drugset / Trial / NCT05206019

Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection

NCT05206019 ↗

Phase 1 Completed 30 enrolled Frontier Biotechnologies Inc.
RandomizedParallel-groupOpen-labelOther

Summary

This is a single-center,randomized,open, single-dose, parallel-design study, which will be only enrolled Chinese healthy volunteers.

Timeline

Start
2022-02-16
Primary completion
2022-04-17
Completion
2022-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Albuvirtide Other / unclassified 320 mg Intravenous

Indications

AIDS